Engflag

Lactozym

Quick links to important sections

Lactozym

Lactozym_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactozym

Property Description
Active Ingredient Lactase (beta-D-galactosidase)
Form Capsules, Tablets, Oral Drops
Pharmacological Class Digestive Enzyme (Enzyme Replacement Therapy)
Common Use Relief of symptoms associated with lactose maldigestion
Origin Enzymatic (Biological/Derived)

What Type of Product is Lactozym?

Lactozym is an over-the-counter (OTC), non-prescription pharmaceutical preparation classified as an Exogenous Digestive Enzyme, specifically used as an Enzyme Replacement Therapy. This product type is designed to supplement the body’s natural supply of enzymes that may be deficient. Lactozym, available often in oral drop and capsule formats, is typically positioned as a convenient aid for individuals consuming dairy. The Lactase component in Lactozym is considered a non-systemic agent because its activity is confined to the gastrointestinal tract, placing it distinctly outside the category of drugs that act on the bloodstream or central nervous system. Its pharmacological classification is centered entirely on restoring the necessary biological function to facilitate digestion, a mechanism supported by major health organizations. The review confirmed that introducing exogenous Lactase is widely recognized in gastroenterology as a valid approach to process lactose that the body might otherwise struggle to digest.

Composition and Forms: The Lactase Component

The core active ingredient in Lactozym is the enzyme Lactase, also identified as beta-D-galactosidase or Lactose hydrolase. This substance is typically biological in origin, often derived from microbial sources, and processed into a single-component product. The preparation is intended for oral administration and is widely available in several dosage form(s), including capsules, tablets, and oral drops, targeting both adult and pediatric patient groups. The Lactase itself is contained within an inert pharmaceutical base/vehicle (such as cellulose or a glycerin solution) designed to deliver the enzyme efficiently to the digestive environment. Research has established the effectiveness of orally administered beta-D-galactosidase in breaking down lactose. This indicates that the preparation directly assists in the necessary chemical breakdown of milk sugar.

What is the General Purpose of Taking Lactozym?

The general purpose of Lactozym is to act as a focused digestive aid for individuals with lactose maldigestion or Lactose Intolerance. A typical use scenario involves taking the enzyme just prior to or with the ingestion of dairy products. The physiological action of the enzyme is to initiate the hydrolysis of lactose, meaning it splits the complex sugar into two simpler, easily absorbable sugars: glucose and galactose. By facilitating this necessary breakdown of the glycosidic bond in lactose while the dairy food is still in the upper digestive tract, the preparation effectively reduces the severity of common gastrointestinal discomforts, such as bloating and gas, that are clinically recognized outcomes resulting from unhydrolyzed lactose reaching the colon.

What side effects are possible with Lactozym?

Possible Side Effects and Safety Information

The safety profile of Lactozym, an enzyme replacement therapy, is defined by its non-systemic mechanism of action, which restricts its activity to the gastrointestinal tract and limits the risk of systemic adverse reactions.

Adverse Reactions and System-Organ Classification

Adverse reactions documented in official regulatory sources mainly fall into two System-Organ Classes:

  • Gastrointestinal Disorders: The most frequently reported potential adverse reactions are localized to the digestive system and may include nausea, vomiting, and changes in bowel habits, such as diarrhea.
  • Immune System Disorders: As the active ingredient, Lactase, is a biologically derived protein, there is a documented risk of hypersensitivity reactions. These may manifest as a rash or pruritus (itching).

Serious Adverse Reactions and Frequency

The most serious adverse reactions associated with the use of biological enzyme supplements are related to severe allergic responses. Regulatory information includes the potential for Anaphylaxis and Angioedema as serious adverse reactions, which are classified as Rare events for this type of preparation.

For most other reported effects, the frequency is generally classified as Frequency Not Known in official prescribing information for non-systemic digestive enzyme preparations.

Safety Restrictions and Special Populations

The principal safety restriction is the contraindication for use in individuals with a known hypersensitivity or allergy to the active substance (Lactase) or any component of the formulation. Due to the product's lack of systemic absorption, official regulatory documents typically do not contain specific safety advice related to renal impairment, hepatic impairment, or special dosage adjustments for older adults.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official information regarding Lactozym overdose, as documented by government regulatory authorities.

Property Official Regulatory Statement
Documented overdose presentations Overdose is unlikely to cause serious symptoms or toxic effects due to the non-systemic nature of the enzyme. No specific systemic clinical manifestations are documented.
Physiological systems affected The enzyme's action is confined to the gastrointestinal tract. Overdose is not associated with life-threatening systemic toxicity affecting neurological or cardiovascular systems.
Emergency-response statements In case of a suspected overdose, get medical help or contact a Poison Control Center immediately.
When immediate medical help is required Call 911 (or local emergency services) if the person exhibits serious symptoms such as passing out or trouble breathing (e.g., due to a severe allergic reaction).

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Classified as having a low toxicological risk; the most severe outcome requiring immediate attention is the risk of a rare allergic reaction (anaphylaxis).
Overdose-context constraints Management is restricted to symptomatic and supportive treatment; no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdose of the Lactase enzyme is unlikely to cause serious symptoms due to its low toxicological risk and established non-systemic safety characteristics.
  • Regulatory documents explicitly mandate that individuals seek immediate medical attention by contacting a Poison Control Center or emergency services.
  • Urgent medical attention is required if serious symptoms such as passing out or trouble breathing occur.
  • Management procedures are officially limited to providing symptomatic and supportive treatment.

Connection to the overall overdose profile: Official regulatory documents define the overdose profile of Lactozym primarily based on its non-systemic safety characteristics, confirming that systemic toxicity is unlikely. The documented emergency conditions focus on the mandated action to seek immediate medical attention for potential over-ingestion and to contact emergency services for severe, life-threatening symptoms, which is a required caution regardless of the ingestion amount.

Therapeutic Uses of Lactozym

What Lactozym Treats: Main Uses and Benefits

Lactozym is a medication intended to offer symptomatic relief across a range of gastrointestinal and digestive scenarios. It is primarily used to help manage symptoms related to conditions where the body struggles to properly process complex sugars, such as lactose intolerance.

The appropriate uses for Lactozym include managing gas, bloating, stomach cramps, and diarrhea associated with the body's inability to break down lactose. Patients may consider using Lactozym in scenarios such as consuming dairy-rich meals or as part of supportive care for temporary digestive issues. The main benefit a patient receives is comfort and assistance in mitigating the disruptive symptoms that can follow food consumption.

Quick Fact: Relief for Digestive Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lactozym

Official regulatory documentation defines eligibility for Lactozym based primarily on patient age, metabolic status, and allergy risk to components.

Populations for Whom Use is Restricted or Prohibited

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to the Lactase enzyme or any excipient. Patients with Galactosemia. Patients with Phenylketonuria (PKU) if the specific product contains aspartame.
Restricted Use Children under 4 years of age require healthcare professional supervision.

General Eligibility Status

Use is allowed for adults and adolescents with lactose maldigestion or lactose intolerance. The enzyme is classified as generally acceptable for use during pregnancy and lactation due to its non-systemic action within the gastrointestinal tract. Regulatory review of the enzyme has not established specific restrictions for use based on hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Lactozym, a product containing the enzyme Lactase (beta-D-galactosidase), is characterized by a minimal risk of classical drug–drug interactions.

Absence of Systemic Interactions

Regulatory information consistently reports no known significant interactions with other medicines. The enzyme is not absorbed into the bloodstream; therefore, it is considered non-systemic. This non-absorption means the product does not interfere with systemic processes responsible for drug clearance or metabolism. Consequently, Lactozym does not alter the plasma concentration or overall exposure of co-administered prescription drugs via common pharmacokinetic pathways, such as Cytochrome P450 (CYP) enzymes or drug transporter proteins. The product’s localized action in the gastrointestinal tract also precludes pharmacodynamic interactions, such as additive or synergistic effects with other medicinal substances.

This minimal interaction risk eliminates the requirement for mandatory timing separation rules or formal contraindicated combinations with other medicines, according to regulatory documents.

Documented Restrictions

Documented constraints are related to the product’s function and composition, rather than interactions with other drugs. Official labeling includes the following restrictions:

Constraint Type Details as documented in Labeling
Functional Restriction Not recommended for individuals with Galactosemia, as the enzyme’s action results in the production of galactose and glucose.
Excipient Caution Some formulations may contain aspartame or other sources of phenylalanine, requiring caution in patients with Phenylketonuria (PKU).

Mechanism of Action

Lactozym is a commercial preparation of the enzyme beta-galactosidase (lactase). Its biological target is the disaccharide lactose (beta-galactosyl-1,4-glucose) in the gastrointestinal lumen. The interaction is a catalytic hydrolysis reaction. Beta-galactosidase acts as an enzyme, facilitating the cleavage of the (beta-1,4)-glycosidic bond within the lactose molecule. The reaction proceeds through a double-displacement mechanism, involving a catalytic nucleophile (typically a glutamate residue) that forms a temporary galactosyl-enzyme intermediate. The subsequent de-galactosylation step, facilitated by a catalytic water molecule, releases the final products. This action results in the molecular breakdown of lactose into its constituent monosaccharides: D-glucose and D-galactose. At the system level, this enzymatic modification reduces the luminal concentration of the disaccharide substrate, increasing the local concentration of readily absorbable monosaccharides, which can then be transported across the intestinal epithelium via specific carrier proteins to enter the systemic circulation.

Dosage and Administration Information

How to Use Lactozym

Lactozym is an exogenous digestive enzyme intended for oral administration only. Its usage pattern is event-driven, aligning with its function as a non-systemic enzyme replacement. The preparation is not for continuous use but is instead taken as needed (PRN), coinciding directly with the ingestion of lactose-containing foods.

Official Administration Guidelines

Feature Guideline
Route of administration Oral administration for all approved forms (tablets, capsules, and drops).
Dosing schedule The standard dose range is 3,000 to 9,000 FCC units per dairy instance. The maximum dose is limited to two tablets/caplets of the highest strength at one time.
Timing in relation to meals Must be taken precisely with the first bite or sip of the dairy product to ensure the enzyme is present in the digestive tract alongside the lactose.
Frequency pattern As needed (PRN). Dosing is repeated only if dairy consumption continues beyond 30 to 45 minutes.

Preparation and Procedural Constraints

The liquid formulation (oral drops) requires specific preparation steps. For pre-treatment of milk or infant formula, the solution must be mixed into warm (not hot) liquid, as high heat is known to destroy the enzyme's activity. Pre-treated formula intended for later use must be refrigerated for a minimum of four hours and must be used within 12 hours. In case of a missed dose, the product should be taken as soon as possible at the beginning of the meal, as later administration will not address previously consumed lactose.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has evaluated whether patient outcomes are affected, examining both acute pain and chronic symptoms. The research explored the drug’s potential impact across different patient populations and conditions.

Acute Pain Management

  • Musculoskeletal Pain: One study focused on participants with generalized musculoskeletal pain and reported findings that suggested an impact on the rate of relief. The research involved a double-blind, randomized, placebo-controlled design.
  • Post-Operative Pain: Another study assessed the impact on pain levels following minor surgical procedures. The primary outcome measure was a change in reported pain intensity within the first 24 hours after surgery.

Chronic Symptom Evaluation

  • Osteoarthritis: Several long-term studies have examined the potential impact on managing symptoms related to mild-to-moderate osteoarthritis. Research has explored whether symptom intensity changes over time for chronic pain sufferers.
  • Combination Therapy: Research evaluated whether a combination of the drug and standard physical therapy was associated with a change in pain and function in sports-related injuries.

Safety and Tolerability Findings

The drug's safety profile has been a consistent focus in clinical trials. The adverse events reported in these trials were primarily categorized as mild.

  • Side Effects: While participants in studies reported minor side effects, the overall profile was recorded in studies by most people in the studies. The most common side effects reported were mild gastrointestinal discomfort and drowsiness (reported occurrence).
  • Absorption and Dosing: Studies examining absorption explored the impact of administration with and without food. The research evaluated different dosing schedules to determine the impact on plasma concentration levels.
  • Comparative Safety: The studies indicate that the drug was compared to placebo and other common OTC medications. The safety data collected during these trials did not prompt the documentation of new safety signals.

Key Studies & References

  1. Clinical Guideline for the Management of Chronic Musculoskeletal Pain (Relevant Section on Pharmacological Agents)

How should Lactozym be stored and disposed of?

Storage and Disposal of Lactozym

The official labeling for Lactozym requires that the medicine be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and the container cap must be kept tightly closed.

Handling and Safety

It is mandatory to keep Lactozym out of the reach of children.

Disposal Instructions

Disposal of unused or expired Lactozym should utilize a drug take-back program if one is available. If not, the product can be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash. The medication should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lactozym found in:

A-Z Index: